{"Welcome.html": {"id": "Welcome.html", "text": "Welcome", "displayed_text": "Welcome"}, "Task.html": {"id": "Task.html", "text": "Task", "displayed_text": "Task"}, "ChangeTypes.html": {"id": "ChangeTypes.html", "text": "ChangeTypes", "displayed_text": "ChangeTypes"}, "Consent.html": {"id": "Consent.html", "text": "Consent", "displayed_text": "Consent"}, "Navigation.html": {"id": "Navigation.html", "text": "Navigation", "displayed_text": "Navigation"}, "Medicine_350": {"DOI": "10.1016/j.jalz.2018.06.2856", "id": "Medicine_350", "News Finding": "They say their findings could lead to new ways to identify people at high risk for Alzheimer's.", "Paper Finding": "In contrast, a smaller population-based cohort of 812 in three French cities showed substantially increased dementia risk (odds ratio 3.9, [1.5, 10.4]) in participants with glaucoma during 3 years, but only analyzed 2436 person-years, roughly 1/6 of our follow-up .", "News Context": "They say their findings could lead to new ways to identify people at high risk for Alzheimer's. \"The main message from this study is that ophthalmologists should be more aware of the risks of developing dementia for people with these eye conditions and primary care doctors seeing patients with these eye conditions might be more careful on checking on possible dementia or memory loss,\" Lee explained in a university news release. Patients with age-related macular degeneration, diabetic retinopathy or glaucoma had a 40 to 50 percent greater risk of Alzheimer's disease than those without the eye conditions, the researchers said.", "Paper Context": "Similarly, a retrospective study using 5% of Medicare claims data revealed no increased AD risk in people with glaucoma (n 5 63,235) compared with propensity score-matched people without glaucoma during 14 years of follow-up (HR 0.91, [0.88, 0.93]) . In contrast, a smaller population-based cohort of 812 in three French cities showed substantially increased dementia risk (odds ratio 3.9, [1.5, 10.4]) in participants with glaucoma during 3 years, but only analyzed 2436 person-years, roughly 1/6 of our follow-up . The Rotterdam Study followed 1438 dementia-free participants aged 75 years for an average of 25 months and found increased AD risk in those with advanced AMD (HR 2.1, [1.1, 4.3] ), but this became insignificant with smoking and atherosclerosis included in the model .", "scores": "[4.0, 3.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 3.6666666666666665, "source": "news", "News URL": "http://ct.moreover.com/?a=34792864437&p=1pl&v=1&x=POVsoSxsrI9yWH7psyoAxQ", "text": "<b>Reported finding:</b> They say their findings could lead to new ways to identify people at high risk for Alzheimer's.<br><b>Paper finding:</b> In contrast, a smaller population-based cohort of 812 in three French cities showed substantially increased dementia risk (odds ratio 3.9, [1.5, 10.4]) in participants with glaucoma during 3 years, but only analyzed 2436 person-years, roughly 1/6 of our follow-up .", "displayed_text": "<b>Reported finding:</b> They say their findings could lead to new ways to identify people at high risk for Alzheimer's.<br><b>Paper finding:</b> In contrast, a smaller population-based cohort of 812 in three French cities showed substantially increased dementia risk (odds ratio 3.9, [1.5, 10.4]) in participants with glaucoma during 3 years, but only analyzed 2436 person-years, roughly 1/6 of our follow-up ."}, "Medicine_8": {"DOI": "10.1001/jama.2013.277165", "id": "Medicine_8", "News Finding": "Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used.", "Paper Finding": "Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used (Table 2 ; and eTable 4 in the Supplement), and without interaction across patient subsets, including demographics, previous treatment, risk scores, biomarkers or management (eFigure 3B and eFigure 4 in the Supplement).", "News Context": "Patients in the otamixaban group had about double the rate of the primary safety outcome of Thrombosis in Myocardial Infarction major or minor bleeding at day 7 compared with patients in the combination of UFH-plus-eptifibatide group (3.1 percent vs. 1.5 percent). Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used. Study anticoagulant was discontinued because of bleeding in 242 patients (4.7 percent) in the otamixaban group and in 95 patients (1.7 percent) in the UFH-plus-eptifibatide group.", "Paper Context": "Patients in the otamixaban group had an increased rate of the primary safety outcome of TIMI major or minor bleeding at day 7 compared with patients in the combination of UFHplus-eptifibatide group (3.1% vs 1.5%; RR, 2.13 [95% CI, 1.63-2.78]; P < .001; Table 2 ). Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used (Table 2 ; and eTable 4 in the Supplement), and without interaction across patient subsets, including demographics, previous treatment, risk scores, biomarkers or management (eFigure 3B and eFigure 4 in the Supplement). Study anticoagulant was discontinued because of bleeding in 242 patients (4.7%) in the otamixaban group and in 95 patients (1.7%) in the UFH-pluseptifibatide group (P < .001).", "scores": "[4.0, 4.0, 5.0, 5.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 4.4, "source": "news", "News URL": "http://www.sciencedaily.com/releases/2013/09/130901153354.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+News%29", "text": "<b>Reported finding:</b> Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used.<br><b>Paper finding:</b> Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used (Table 2 ; and eTable 4 in the Supplement), and without interaction across patient subsets, including demographics, previous treatment, risk scores, biomarkers or management (eFigure 3B and eFigure 4 in the Supplement).", "displayed_text": "<b>Reported finding:</b> Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used.<br><b>Paper finding:</b> Otamixaban consistently increased all types of bleeding events, regardless of the severity or bleeding classification scheme used (Table 2 ; and eTable 4 in the Supplement), and without interaction across patient subsets, including demographics, previous treatment, risk scores, biomarkers or management (eFigure 3B and eFigure 4 in the Supplement)."}, "Medicine_401": {"DOI": "10.1371/journal.pone.0193399", "id": "Medicine_401", "News Finding": "For instance, more than one in three care home staff were rarely aware of a resident being taken outside of the home for their enjoyment, and 15% said activities were almost never planned around a resident's interests.", "Paper Finding": "Many care home staff were never or almost never aware of a resident being taken out of the home for their enjoyment (34%, n = 520); or an activity planned around a resident's interests (5%, n = 234).", "News Context": "advertisement\n\nPositive behaviours were reported to be much more common than abusive behaviours, however some positive but time-consuming behaviours were notably infrequent. For instance, more than one in three care home staff were rarely aware of a resident being taken outside of the home for their enjoyment, and 15% said activities were almost never planned around a resident's interests. v\"Carers can't just be told that care should be person-centred -- they need to be given the support and training that will enable them to deliver it,\" she said.", "Paper Context": "Most staff reported positive care behaviours, but specific person-centred activities were sometimes infrequent. Many care home staff were never or almost never aware of a resident being taken out of the home for their enjoyment (34%, n = 520); or an activity planned around a resident's interests (5%, n = 234). 763 (5%; 95% Confidence Interval (CI) 47% to 54%) of care home staff reported carrying out or observing potentially abusive or neglectful behaviours at least sometimes in the preceding 3 months; some abuse was reported as happening \"at least sometimes\" in 9/92 care homes.", "scores": "[3.0, 5.0, 5.0, 5.0]", "field": "Medicine", "split": "val", "final_score": 4.5, "source": "news", "News URL": "http://ct.moreover.com/?a=33617077814&p=1pl&v=1&x=ohjazzVxcRa1ao0LE5QCcQ", "text": "<b>Reported finding:</b> For instance, more than one in three care home staff were rarely aware of a resident being taken outside of the home for their enjoyment, and 15% said activities were almost never planned around a resident's interests.<br><b>Paper finding:</b> Many care home staff were never or almost never aware of a resident being taken out of the home for their enjoyment (34%, n = 520); or an activity planned around a resident's interests (5%, n = 234).", "displayed_text": "<b>Reported finding:</b> For instance, more than one in three care home staff were rarely aware of a resident being taken outside of the home for their enjoyment, and 15% said activities were almost never planned around a resident's interests.<br><b>Paper finding:</b> Many care home staff were never or almost never aware of a resident being taken out of the home for their enjoyment (34%, n = 520); or an activity planned around a resident's interests (5%, n = 234)."}, "Medicine_174": {"DOI": "10.1016/j.cell.2016.09.056", "id": "Medicine_174", "News Finding": "The second surprise came with the unearthing of CD81's inner cavity and the discovery that it can hold a cholesterol molecule.", "Paper Finding": "The tetraspanin CD81 contains a large intramembrane cavity occupied by cholesterol, indicating the potential for functional modulation by small molecules.", "News Context": "\"It's different from all prior predictions,\" said Blacklow. The second surprise came with the unearthing of CD81's inner cavity and the discovery that it can hold a cholesterol molecule. That got the team especially excited, because it revealed that researchers can now try to manipulate CD81 using cholesterol or other small molecules.", "Paper Context": "Cholesterol binding appears to modulate CD81 activity in cells, suggesting a potential mechanism for regulation of tetraspanin function. The tetraspanin CD81 contains a large intramembrane cavity occupied by cholesterol, indicating the potential for functional modulation by small molecules. The development of specialized cell-cell interactions and new cell types likely selected for the duplication and differentiation of tetraspanins that evolved to effect specific functions.", "scores": "[4.0, 4.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "news", "News URL": "http://feedproxy.google.com/~r/TechnologyOrg/~3/Ay74vlkGcfw/", "text": "<b>Reported finding:</b> The second surprise came with the unearthing of CD81's inner cavity and the discovery that it can hold a cholesterol molecule.<br><b>Paper finding:</b> The tetraspanin CD81 contains a large intramembrane cavity occupied by cholesterol, indicating the potential for functional modulation by small molecules.", "displayed_text": "<b>Reported finding:</b> The second surprise came with the unearthing of CD81's inner cavity and the discovery that it can hold a cholesterol molecule.<br><b>Paper finding:</b> The tetraspanin CD81 contains a large intramembrane cavity occupied by cholesterol, indicating the potential for functional modulation by small molecules."}, "Experience.html": {"id": "Experience.html", "text": "Experience", "displayed_text": "Experience"}, "End.html": {"id": "End.html", "text": "End", "displayed_text": "End"}}